Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- GRVY +13.3%, ARLP +7.1%, RDUS +2.4%, MRNS +2.1%, DO +1%, CAH +0.6%
M&A news:
- HBHC +2.8% (acquired assets and liabilities of First NBC Bank (FNBC) from the FDIC)
Other news:
- XXII +42.9% (FDA has granted the co authorization to conduct a clinical trial studying its BRAND B)
- ONVO +5.2% (announces a collaboration with the University of Virginia to develop 3D bioprinted tissues for volumetric muscle loss injury)
- TWTR +4.1% (CEO Jack Dorsey discloses the purchase of 574K shares; also to partner with Bloomberg for a streaming news service, according to the WSJ)
- MICT +4% (receives a purchase order valued at approximately $1,060,000 for its recently released TREQr5 product from a leading fleet management solutions provider)
- KERX +3.5% (announces that an additional large Medicare Part D plan sponsor has added Auryxia to its Medicare Part D plan formularies, effective June 1)
- FGP +2.7% (amends its revolving credit facility to provide covenant relief)
- AMD +0.9% (trading higher ahead of earnings after market close today)
Analyst comments:
- HESM +4.5% (initiated with a Buy at Goldman)
- LC +3.1% (upgraded to Positive from Neutral at Susquehanna)
- FSLR +1.9% (upgraded to Neutral from Underperform at Credit Suisse)
- BOLD +1.7% (initiated with a Outperform at Leerink Partners)
- ADSK +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- COF +0.6% (upgraded to Buy from Hold at Deutsche Bank)
- CNHI +0.5% (upgraded to Neutral from Underweight at JP Morgan)
Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- TIS -7.6%, (also does not declare dividend), CCRC -2.5%, DISH -1.5%
M&A news:
- GNW -6.4% (Genworth Financial and Oceanwide provide update on CFIUS application)
Other news:
- AEZS -63% (announces that the ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint)
- NTRP -50.8% (top-line results from its Phase 2 study (-202 Study) of Bryostatin-1)
- ITCI -41.4% (FDA has confirmed that the results of Study ITI-007-302 do not preclude them from submitting an NDA based on the efficacy studies they have conducted to date)
- MTNB -5.1% (entered into a Controlled Equity Offering Sales Agreement with Cantor pursuant to the registration statement on Form S-3)
- ANY -3.2% (files for 22,415,550 common share offering by holders)
- SIX -0.5% (to repurchase 5,060,628 shares of common stock from H Partners/affiliated funds at $61.36/share)
Analyst comments:
- WAIR -4.1% (downgraded to Neutral from Buy at Citigroup)
- SSW -3.7% (downgraded to Underperform from Neutral at Credit Suisse)
- WDC -1.5% (downgraded to Hold from Buy at Jefferies)
- SHOP -1.2% (downgraded to Neutral at Monness Crespi & Hardt)